Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Matthew S. Davids(Harvard University), Andrew W. Roberts(The Royal Melbourne Hospital), Lori A. Gressick(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Nikita Rudersdorf(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), Nicholas P. Montalvo(AbbVie (United States)), David C.S. Huang(The University of Melbourne), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Ccrp(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Jianning Yang(AbbVie (United States)), Thomas P. Miller(Queen Elizabeth University Hospital), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Martin Dunbar(AbbVie (United States))
Cited by 69
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k